FR-BT-0002

Epigenetic Reprogramming — Biological Age Reversal Without Identity Loss

Epigenetic reprogramming can reverse biological age in living organisms without loss of cellular identity.

EscalatingVS-02·since 2026-08-29

Assessment trajectory

Escalatingstate held · last assessed 2026-08-29

Verification Matrix

Verification position derived from the record’s assessments; dates show when Faultline first recorded each stage.

VS-01

Assertion

—

VS-02

Published evidence

Current from 2026-08-29 — present

VS-03

Audit

First recorded 2024-01-15

VS-04

Replication

—

VS-05

Operation

—

Stage first recorded Current verification position Not yet recorded

State Warrant

Current stateEscalatingVS-02

Why this state?PA-006 final replication trial. New evidence provenance captured at admission from Life Biosciences' June 9, 2026 first-patient-dosed announcement and ClinicalTrials.gov NCT07290244. Opportunistic legacy enrichment also verified IN-006 against Life Biosciences' January 28, 2026 IND announcement and the trial registry; no factual correction was required.

Assessment summaryPA-006 provenance-in-review final replication confirms that ER-100 has progressed from regulatory clearance to actual human dosing: Life Biosciences reported the first participant dosed on June 9, 2026, and ClinicalTrials.gov lists NCT07290244 as recruiting. This is a substantive operational advance because the claim is now being tested directly in humans rather than only authorised for testing. It does not yet satisfy AT-001 or the governing claim. No results are posted, so there is still no human evidence establishing safety at partial-reprogramming doses, biological-age reversal, preserved cellular identity, or validated functional rejuvenation. BN-001 therefore remains unresolved. ESCALATING / VS-02 is retained pending human outcome evidence.

State entered2024-01-15

Last reaffirmed2026-08-29

Mechanisms

Causal mechanisms recorded for this claim. The State Warrant above remains the authoritative current assessment.

Resistance MechanismRM-001

Safety window for partial reprogramming in humans. OSKM expression is potently oncogenic at high doses or sustained expression. The therapeutic window — sufficient expression to reverse epigenetic aging marks without inducing dedifferentiation or tumour formation — has been demonstrated in mice but not characterised in humans or non-human primates at clinically relevant doses. The safety constraint is the primary obstacle to human trials: no regulatory agency will approve a Phase I trial without substantially more NHP safety data. The resistance mechanism is not that partial reprogramming is impossible but that establishing the safety window in humans requires a multi-year preclinical programme before human exposure can begin.

BottleneckBN-001

Biological age measurement validity. The claim requires that biological age be reversed. The primary measurement tool — epigenetic clocks — is contested as a surrogate for genuine rejuvenation. Clocks can be reset by interventions that may not produce functional benefit. If clock reversal and functional rejuvenation are dissociable — if the clock can be moved without changing organismal biology in ways that matter — then the claim's satisfaction conditions are ambiguous. This is a measurement validity bottleneck: the claim cannot be confirmed or contested cleanly until the relationship between clock readings and functional outcomes is established. This is structurally distinct from FR-BT-0001's lexical bottleneck ("meaningfully extend"): that was a threshold dispute; this is a measurement validity dispute. Both are bottlenecks from absence of an agreed measurement framework, as the verdict on FR-BT-0001 observed.

AttractorAT-001

First human safety data and validated functional outcome biomarkers. Two developments would materially advance this record: first, Phase I human trials demonstrating safe OSKM induction at partial reprogramming doses with measurable epigenetic clock reversal and no adverse dedifferentiation signals; second, validated functional outcome biomarkers that correlate with clock reversal and demonstrate that clock reduction predicts downstream health benefits. The first would open the human evidence path; the second would resolve BN-001. Neither is present; both are on active development timelines in the field.

Assessment History

2024-01-15

Initial assessment — Escalating

The claim has not been satisfied in humans. Partial epigenetic reprogramming without loss of cellular identity has been demonstrated in multiple mouse models and is extending toward non-human primates. No human clinical trials have been initiated. The biological mechanism is well-established: OSKM and related factors can reset epigenetic age marks; partial expression can do so without completing dedifferentiation; and the process produces functional improvements in at least some mouse tissues. The claim's human clinical evidence gap remains complete: no partial reprogramming therapy has yet entered a human trial. The pressure state is ESCALATING: the mechanism is well established across multiple mouse models and the field is heavily capitalised (INST-003), but whether partial reprogramming is safe and effective in humans — and whether epigenetic clock reversal constitutes genuine rejuvenation rather than a movable measurement (BN-001) — remains entirely untested outside model organisms.

Verification Stage: VS-03 after ratified review (stored code VS-02 preserved).^*

2026-06-29

Reassessed, no change — Escalating

The human clinical evidence gap that AS-001 identified as complete is now closing. Life Biosciences has received FDA IND clearance for ER-100, a partial OSK reprogramming therapy, with a stated trial start of Q1 2026 — the first human trial of any partial epigenetic reprogramming therapy. This is the first half of AT-001's named resolution attractor ("first human safety data and validated functional outcome biomarkers"); the second half — actual safety and clock-reversal data — does not yet exist, since the trial has only just been cleared to begin, not completed or reported. The pressure state remains ESCALATING rather than moving to RESOLVING: clearance to run a trial is a regulatory and operational milestone, not efficacy or safety evidence. BN-001 (clock validity as a rejuvenation surrogate) is unaffected by this development and remains the record's primary interior bottleneck regardless of how the ER-100 trial proceeds. This assessment exists to record that the record's own named attractor condition has begun to materialise, not to anticipate its outcome.

Sourced from: Life Biosciences public statements and lifespan.io coverage of the FDA IND clearance for ER-100 (reported Feb 2026). Accessed via secondary reporting; the FDA clearance itself and Life Biosciences' own trial registration were not independently verified at primary source. Given this is presented as a significant evidentiary development, primary verification (e.g. via ClinicalTrials.gov registration) is recommended before this assessment is treated as fully confirmed.

Verification Stage: VS-03 after ratified review (stored code VS-02 preserved).^*

2026-08-29

Reassessed, no change — Escalating

PA-006 provenance-in-review final replication confirms that ER-100 has progressed from regulatory clearance to actual human dosing: Life Biosciences reported the first participant dosed on June 9, 2026, and ClinicalTrials.gov lists NCT07290244 as recruiting. This is a substantive operational advance because the claim is now being tested directly in humans rather than only authorised for testing. It does not yet satisfy AT-001 or the governing claim. No results are posted, so there is still no human evidence establishing safety at partial-reprogramming doses, biological-age reversal, preserved cellular identity, or validated functional rejuvenation. BN-001 therefore remains unresolved. ESCALATING / VS-02 is retained pending human outcome evidence.

PA-006 final replication trial. New evidence provenance captured at admission from Life Biosciences' June 9, 2026 first-patient-dosed announcement and ClinicalTrials.gov NCT07290244. Opportunistic legacy enrichment also verified IN-006 against Life Biosciences' January 28, 2026 IND announcement and the trial registry; no factual correction was required.

Claim Lineage

Historical narrative recorded for this claim. It does not override the current State Warrant.

2006

Yamanaka reprogramming. Full OSKM reprogramming resets epigenetic age to near-zero. Cellular identity destroyed. The age reversal principle is established; the identity preservation constraint opens as the key unsolved problem.

2016

Cyclic partial reprogramming in progeria mice. Ocampo et al. demonstrate lifespan extension without tumour formation through intermittent OSKM. The claim becomes experimentally tractable. Partial reprogramming as a therapeutic concept enters the field.

2019–21

Epigenetic clock reversal demonstrated in multiple tissues. Lu et al. and others demonstrate partial reprogramming in specific tissues (retina, muscle) with functional benefit in aged mice. The claim's mechanistic basis is substantially established in rodent models.

2022–23

Major capitalisation and NHP extension. Altos Labs, Retro Biosciences, and related companies raise billions. NHP studies begin. The field transitions from academic research to clinical development programme. Human trials remain absent.

2023–24

Clock validity dispute matures. The measurement validity of epigenetic clocks as rejuvenation surrogates is formally contested. The field must resolve whether clock reversal is sufficient evidence for the claim or whether functional outcomes are required independently.

2026

ER-100 enters human testing. FDA IND clearance is followed by first-participant dosing in the Phase 1 NCT07290244 trial. Human exposure is now established, but no safety, efficacy, age-reversal, identity-preservation, or functional-outcome results have been reported.

Open Questions

Questions retained in this record. The current State Warrant may have narrowed or reframed earlier questions.

OQ-001

INST-003 (Altos Labs capitalisation) constitutes the fifth occurrence of anticipatory institutional evidence. RN-004 was issued at three occurrences and noted that a fourth occurrence would warrant an update. A fifth occurrence in a new programme strengthens the case for RN-004 update further. Is a pattern now visible across three programmes?

Raised 2024-01-15

OQ-002

The clock validity dispute (INST-004) is structurally similar to the FR-AI-0006 mechanism coherence dispute: both ask whether a measurement tool is tracking the thing it purports to measure. Does this suggest a general phenomenon — measurement validity as a resistance mechanism — or is it specific to certain frontier domains?

Raised 2024-01-15

OQ-003

FR-BT-0001 and FR-BT-0002 are structurally adjacent but not related through evidence or ancestry in the way FR-AM-0001 and FR-AM-0002 were related. They share a programme and a validation constraint but have independent evidence trails. Does programme membership without evidence relationship constitute a weaker or different kind of programme structure than the PROG-AM genetic relationship?

Raised 2024-01-15

OQ-004

ER-100's trial is the first direct test of AT-001's named attractor condition. When (or if) it reports results, should the pressure state move directly to RESOLVING, or does a single trial — likely small, likely focused on safety rather than efficacy at Phase 1 — only partially satisfy an attractor that names both safety data and validated functional biomarkers? The record should decide this before the trial reports, not in reaction to whatever it finds.

Raised 2026-06-29

Mutation Log

Mutation	Date	Field	Prior value	Current value
M-014	2026-09-06	description_restored	Legacy ingestion cutoffs: mechanisms:RM-001, mechanisms:BN-001, mechanisms:AT-001	Source-restored complete descriptions
M-013	2026-08-29	provenance_enriched	IN-006 without structured provenance	IN-006 sources[] added
M-012	2026-08-29	assessment_issued	AS-002	AS-003
M-011	2026-08-29	instance_added	—	IN-007
M-010	2026-07-09	description_reordered	—	DESCRIPTION-REORDERED
M-009	2026-07-08	reference_corrected	—	REFERENCE-CORRECTED
M-008	2026-06-29	open_question_raised	—	OQ-RAISED
M-007	2026-06-29	assessment_issued	AS-001	AS-002
M-006	2026-06-29	instances_logged	—	INSTANCES-LOGGED
M-005	2024-01-15	diagnostic_tendency_confirmed	—	DIAGNOSTIC-TENDENCY-CONFIRMED
M-004	2024-01-15	mechanisms_recorded	—	MECHANISMS-RECORDED
M-003	2024-01-15	assessment_issued	—	ASSESSMENT-ISSUED
M-002	2024-01-15	instances_logged	—	INSTANCES-LOGGED
M-001	2024-01-15	record_created	—	RECORD-CREATED

Evidence Sources

7 instances on recordShow sources ↓Hide ↑

IN-001Yamanaka factors and iPSC reprogramming — the theoretical basis and its limitssupportive

IN-002Ocampo et al. and cyclic reprogramming — partial reprogramming in micesupportive

IN-003Altos Labs, Retro Biosciences, and partial reprogramming race — field industrialisespartial

IN-004Clock validity debate — does epigenetic age reversal reflect genuine rejuvenation?contesting

IN-005Partial reprogramming in non-human primates — bridging toward human evidencepartial

IN-006Life Biosciences (ER-100) — FDA IND clearance, first human partial-reprogramming trial1. Life Biosciences (2026), FDA Clearance of IND Application for ER-100 in Optic Neuropathies · January 28, 2026 announcement; Phase 1 NCT072902442. ClinicalTrials.gov, NCT07290244 — Evaluating ER-100 for Safety in People With Glaucoma or NAION · Study overview and registration datessupportive

IN-007ER-100 enters human dosing — first participant treated in Phase 11. Life Biosciences (2026), First Patient Dosed in Phase 1 Trial of ER-100 for Optic Neuropathies · June 9, 2026 announcement2. ClinicalTrials.gov, NCT07290244 — Evaluating ER-100 for Safety in People With Glaucoma or NAION · Recruiting status; Phase 1; sponsor and study overviewsupportive